AbClon Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
67
- Stock Symbol
-
174900
- Investments
-
2
- Share Price
-
$17.49
- (As of Friday Closing)
AbClon General Information
Description
Abclon Inc is engaged in the research and development of antibody drugs. Its business sector is divided into Antibody drug and Bio CRO.
Contact Information
Website
www.abclon.comCorporate Office
- Number 1401
- 285, Digital-ro, Guro-gu
- Seoul, 08381
- South Korea
Corporate Office
- Number 1401
- 285, Digital-ro, Guro-gu
- Seoul, 08381
- South Korea
AbClon Timeline
AbClon Stock Performance
As of 20-Nov-2026, AbClon’s stock price is $17.49. Its current market cap is $349M with 20M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $17.49 | $18.28 | $11.17 - $63.72 | $349M | 20M | 182K | -$0.62 |
AbClon Financials Summary
As of 30-Jun-2026, AbClon has a trailing 12-month revenue of $3.66M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 337,184 | 561,560 | 167,879 | 174,735 |
| Revenue | 3,657 | 3,312 | 1,715 | 2,200 |
| EBITDA | (11,803) | (11,806) | (10,386) | (8,198) |
| Net Income | (12,005) | (12,583) | (11,947) | (9,870) |
| Total Assets | 41,802 | 49,129 | 32,711 | 35,258 |
| Total Debt | 4,821 | 4,920 | 11,712 | 9,778 |
AbClon Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AbClon Patents
AbClon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4713367-A1 | Anti-cd30 antibody and chimeric antigen receptor comprising thereof | Pending | 18-May-2023 | ||
| US-12668640-B2 | Anti-cd30 antibody and chimeric antigen receptor comprising thereof | Active | 18-May-2023 | ||
| US-20240392023-A1 | Anti-cd30 antibody and chimeric antigen receptor comprising thereof | Active | 18-May-2023 | ||
| WO-2024237521-A1 | Anti-cd30 antibody and chimeric antigen receptor comprising thereof | Inactive | 18-May-2023 | ||
| JP-2026518729-A | Anti-cd30 antibody and chimeric antigen receptor containing the same | Pending | 18-May-2023 | C07K16/2878 |
AbClon Signals
AbClon Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
AbClon Investments (2)
AbClon’s most recent deal was a Corporate Asset Purchase with Shingwang (4,276 Square Meter Facility Site in Siheung, South Korea) for . The deal was made on 27-Aug-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Shingwang (4,276 Square Meter Facility Site in Siheung, South Korea) | 27-Aug-2019 | Corporate Asset Purchase | Buildings and Property | ||
| ComArtSystems (Land and Building Property in Seoul, South Korea) | 19-Feb-2018 | Corporate Asset Purchase | Buildings and Property |
AbClon ESG
Risk Overview
Risk Rating
Updated December, 31, 2023
32.53 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Biotechnology
Subindustry
of 394
Rank
Percentile
AbClon FAQs
-
When was AbClon founded?
AbClon was founded in 2010.
-
Where is AbClon headquartered?
AbClon is headquartered in Seoul, South Korea.
-
What is the size of AbClon?
AbClon has 67 total employees.
-
What industry is AbClon in?
AbClon’s primary industry is Drug Discovery.
-
Is AbClon a private or public company?
AbClon is a Public company.
-
What is AbClon’s stock symbol?
The ticker symbol for AbClon is 174900.
-
What is the current stock price of AbClon?
As of 20-Nov-2026 the stock price of AbClon is $17.49.
-
What is the current market cap of AbClon?
The current market capitalization of AbClon is $349M.
-
What is AbClon’s current revenue?
The trailing twelve month revenue for AbClon is $3.66M.
-
What is AbClon’s annual earnings per share (EPS)?
AbClon’s EPS for 12 months was -$0.62.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process